Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996-2016

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical characterization of delayed alcohol-induced headache: A study of 1,108 participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Permanent muscle weakness in hypokalemic periodic paralysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Editorial: Remaining diagnostic issues and start of a treatment era for muscle diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Karen L Madsen
  • Astrid E Buch
  • Bruce H Cohen
  • Marni J Falk
  • Angela Goldsberry
  • Amy Goldstein
  • Amel Karaa
  • Mary K Koenig
  • Colleen C Muraresku
  • Colin Meyer
  • Megan O'Grady
  • Fernando Scaglia
  • Perry B Shieh
  • Jerry Vockley
  • Zarazuela Zolkipli-Cunningham
  • Ronald G Haller
  • John Vissing
Vis graf over relationer

OBJECTIVE: To investigate the safety and efficacy of escalating doses of the semi-synthetic triterpenoid omaveloxolone in patients with mitochondrial myopathy.

METHODS: In cohorts of 8-13, 53 participants were randomized double-blind to 12 weeks of treatment with omaveloxolone 5, 10, 20, 40, 80, or 160 mg, or placebo. Outcome measures were change in peak cycling exercise workload (primary), in 6-minute walk test (6MWT) distance (secondary), and in submaximal exercise heart rate and plasma lactate (exploratory).

RESULTS: No differences in peak workload or 6MWT were observed at week 12 with omaveloxolone treatment vs placebo for all omaveloxolone dose groups. In contrast, omaveloxolone 160 mg reduced heart rate at week 12 by 12.0 ± 4.6 bpm (SE) during submaximal exercise vs placebo, p = 0.01, and by 8.7 ± 3.5 bpm (SE) vs baseline, p = 0.02. Similarly, blood lactate was 1.4 ± 0.7 mM (SE) lower vs placebo, p = 0.04, and 1.6 ± 0.5 mM (SE) lower vs baseline at week 12, p = 0.003, with omaveloxolone 160 mg treatment. Adverse events were generally mild and infrequent.

CONCLUSIONS: Omaveloxolone 160 mg was well-tolerated, and did not lead to change in the primary outcome measure, but improved exploratory endpoints lowering heart rate and lactate production during submaximal exercise, consistent with improved mitochondrial function and submaximal exercise tolerance. Therefore, omaveloxolone potentially benefits patients with mitochondrial myopathy, which encourages further investigations of omaveloxolone in this patient group.

CLINICALTRIALSGOV IDENTIFIER: NCT02255422.

CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, for patients with mitochondrial myopathy, omaveloxolone compared to placebo did not significantly change peak exercise workload.

OriginalsprogEngelsk
TidsskriftNeurology
Vol/bind94
Udgave nummer7
Sider (fra-til)e687-e698
ISSN0028-3878
DOI
StatusUdgivet - 18 feb. 2020

Bibliografisk note

© 2020 American Academy of Neurology.

ID: 61075105